A Neuroimaging and Epigenetic Investigation of Antidepressants in Depression
- Conditions
- Depression Secondary to Other DiseaseDepression
- Interventions
- Registration Number
- NCT00703742
- Lead Sponsor
- Kunming Medical University
- Brief Summary
The purpose of this study is:
1. to find out the structural or functional effects of selective serotonin reuptake inhibitors (SSRI) in major depressive disorder (MDD);
2. find special abnormalities in depression secondary to other disease, e.g., autoimmune disease like systemic lupus erythematosus (SLE).
3. find the relationship between the efficacy of antidepressant and the change of neuroimaging in MDD
4. to find possible predispose to MDD
5. to explore the DNA methylation status in depression;
- Detailed Description
1. to explore the pathology of depression
2. to identify the difference between MDD and depression secondary to other disease ,especially autoimmune disease
3. to explore the effect of gene-environment interaction on the epigenetic regulation of the depression
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 200
- DSM-IV Major Depression or Dysthymia
- Age 18-65
- Physically healthy
- Drug-free
- Body metal (e.g., wire stitches, screws in bones, stainless steel hips)
- History of Psychosis or Epilepsy
- Current (past six months) Substance Use Disorder (illicit drugs and/or alcohol)
- Bipolar I
- Need for wash-out from effective treatment in order to participate
- Pregnant
- High suicide risk
- Currently taking (within 2 weeks; 4 weeks for Fluoxetine) antidepressants
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description A,1 Escitalopram A: Escitalopram, 20 mg/day,8weeks
- Primary Outcome Measures
Name Time Method change of fMRI after medication baseline, 4 weeks, 8 weeks
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
The First Affiliated Hospital of Kunming Medical College
🇨🇳Kunming, Yunnan, China